FDA Panel Backs Six Popular Peptides for Pharmacy Use, but They Are Not Approved Yet

An FDA advisory committee voted to recommend six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) for inclusion on the federal 503A compounding list, allowing licensed pharmacies to prepare them for individual patients with prescriptions, though the FDA has not yet made a final decision and the substances remain unapproved for general use.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.